CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
18F-fluoromethylcholine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01395030
NCT01395030Phase 2Completed
CompareCT.gov

Genomic and Imaging Study for Patients Undergoing Surgery for Liver Cancer

Queen's Medical Center·interventional·Posted Jul 15, 2011·Updated Sep 26, 2018

In Brief

A Phase 2 clinical trial evaluating Computed Tomography, 18F-fluoromethylcholine, and 1 other intervention for Adult Hepatocellular Carcinoma and Localized Resectable Adult Liver Carcinoma. Completed, enrolled 64 participants across 1 site.

Detailed Summary

This clinical trial studies positron emission tomography (PET)/computed tomography (CT) in diagnosing patients with liver cancer undergoing surgical resection. Diagnostic procedures, such as fluorine-18 fluoromethylcholine PET/CT, may help find and diagnose liver cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Hepatocellular Carcinoma, Localized Resectable Adult Liver Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 15, 2011
Enrollment StartAug 15, 2011
Primary CompletionMay 31, 2017
Study CompletionMay 31, 2018
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 15.0 years ago

Interventions

Computed Tomographyother

Undergo FCH PET/CT

18F-fluoromethylcholinedrug

Undergo FCH PET/CT

Positron Emission Tomographyother

Undergo FCH PET/CT